Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 31Neoplasms 8Endometrial Neoplasms 6Neoplasm Metastasis 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Meningioma 3Glioblastoma 3Sarcoma 2Pancreatic Neoplasms 2Oligodendroglioma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Urologic Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Retinoblastoma 1Recurrence 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Squamous Cell 1Neoplasm, Residual 1Multiple Myeloma 1

Interventions

Carboplatin 195Cisplatin 117Paclitaxel 107Pemetrexed 106Docetaxel 96Gemcitabine 89Radiotherapy 83Erlotinib Hydrochloride 58Bevacizumab 55Etoposide 49durvalumab 39pembrolizumab 38Nivolumab 31Specimen Handling 30Magnetic Resonance Spectroscopy 30Irinotecan 27Radiosurgery 26osimertinib 24Gefitinib 24Drug Therapy 23Vinorelbine 22atezolizumab 20Topotecan 20Radiation 16Cetuximab 16Taxes 15Surgical Procedures, Operative 14Neoadjuvant Therapy 13Filgrastim 13Chemotherapy, Adjuvant 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lung Neoplasms × abemaciclib × Clear all
NCT04545710 2024-08-05

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

University of California, San Diego

Phase 2 Active not recruiting
18 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡